Targeting ovarian cancer-initiating cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 157-163

  Murphy, Susan K ^a,b  

^a Division of Gynecologic Oncology   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer stem cells; Cancer initiating cells; Dormancy; Epigenetics; Ovarian cancer; Quiescence; Spheroids

Indexed keywords

8 QUINOLINOL; BRCA1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CELL SURFACE MARKER; DAIDZEIN; GENISTEIN; HERMES ANTIGEN; I KAPPA B; MICRORNA; PYRROLIDINEDITHIOCARBAMATE; SALINOMYCIN; STEM CELL FACTOR RECEPTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR MSX2; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE G0 PHASE; CELL RENEWAL; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DNA METHYLATION; DORMANCY; ENDOMETRIOSIS; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOGENE; OVARY CANCER; PHENOTYPE; REVIEW; TARGET CELL; TRANSCRIPTION REGULATION; TUMOR GROWTH; UTERINE TUBE;

EID: 77950838834     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010790909272     Document Type: Review

References (104)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55(2), 74-108.
2. Smith, L.H.; Morris, C.R.; Yasmeen, S.; Parikh-Patel, A.; Cress, R.D.; Romano, P.S. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer, 2005, 104(7), 1398-1407.
3. Smith, A. A glossary for stem-cell biology. Nature, 2006, 441, 1060.
4. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res., 2006, 66(19), 9339-9344.
5. Mok, S.C.; Kwong, J.; Welch, W.R.; Samimi, G.; Ozbun, L.; Bonome, T.; Birrer, M.J.; Berkowitz, R.S.; Wong, K.K. Etiology and pathogenesis of epithelial ovarian cancer. Dis. Mark., 2007, 23(5-6), 367-376.
6. Dubeau, L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol. Oncol., 1999, 72(3), 437-442.
7. Marquez, R.T.; Baggerly, K.A.; Patterson, A.P.; Liu, J.; Broaddus, R.; Frumovitz, M.; Atkinson, E.N.; Smith, D.I.; Hartmann, L.; Fishman, D.; Berchuck, A.; Whitaker, R.; Gershenson, D.M.; Mills, G.B.; Bast, R.C., Jr.; Lu, K.H. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res., 2005, 11(17), 6116-6126.
8. Nezhat, F.; Datta, M.S.; Hanson, V.; Pejovic, T.; Nezhat, C. The relationship of endometriosis and ovarian malignancy: a review. Fertil. Steril., 2008, 90(5), 1559-1570.
9. Vlahos, N.F.; Kalampokas, T.; Fotiou, S. Endometriosis and ovarian cancer: A review. Gynecol. Endocrinol., 2009, 28, 1-7.
10. Auersperg, N.; Woo, M.M.M. Development and differentiation of the ovarian surface epithelium: cues for the basis of its malignant potential. In The Ovary; Leung, P. C. T.; Adashi, E. Y., Eds. 2nd ed.; Elsevier Academic Press: San Diego, 2004; pp. 579-590.
11. Collaborative Group on Epidemiological Studies of Ovarian, C.; Beral, V.; Doll, R.; Hermon, C.; Peto, R.; Reeves, G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 2008, 371(9609), 303-314.
12. Murdoch, W.J.; Townsend, R.S.; McDonnel, A.C. Ovulationinduced DNA damage in ovarian surface epithelial cells of ewes: prospective regulatory mechanisms of repair/survival and apoptosis. Biol. Reprod., 2001, 65(5), 1417-1424.
13. Murdoch, W.J.; Martinchick, J.F. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp. Biol. Med., 2004, 229(6), 546-552.
14. Murdoch, W.J. Carcinogenic potential of ovulatory genotoxicity. Biol. Reprod., 2005, 73(4), 586-590.
15. Levanon, K.; Crum, C.; Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol., 2008, 26(32), 5284-5293.
16. Deligdisch, L.; Einstein, A.J.; Guera, D.; Gil, J. Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Cancer, 1995, 76(6), 1027-1034.
17. Scully, R.E. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int. J. Gynaecol. Obstet., 1995, 49 (Suppl.), S9-15.
18. Scully, R.E. Pathology of ovarian cancer precursors. J. Cell Biochem. Suppl., 1995, 23, 208-218.
19. Dubeau, L. The cell of origin of ovarian epithelial tumours. Lancet Oncol., 2008, 9(12), 1191-1197.
20. Carcangiu, M.L.; Radice, P.; Manoukian, S.; Spatti, G.; Gobbo, M.; Pensotti, V.; Crucianelli, R.; Pasini, B. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int. J. Gynecol. Pathol., 2004, 23(1), 35-40.
21. Piek, J.M.; van Diest, P.J.; Zweemer, R.P.; Jansen, J.W.; Poort-Keesom, R.J.; Menko, F.H.; Gille, J.J.; Jongsma, A.P.; Pals, G.; Kenemans, P.; Verheijen, R.H. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol., 2001, 195(4), 451-456.
22. Berchuck, A.; Kohler, M.F.; Marks, J.R.; Wiseman, R.; Boyd, J.; Bast, R.C., Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol., 1994, 170(1 Pt 1), 246-252.
23. Folkins, A.K.; Jarboe, E.A.; Saleemuddin, A.; Lee, Y.; Callahan, M.J.; Drapkin, R.; Garber, J.E.; Muto, M.G.; Tworoger, S.; Crum, C.P. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol., 2008, 109(2), 168-173.
24. Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.R.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.; Gordon, R.W.; Cramer, D.W.; McKeon, F.D.; Crum, C.P. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol., 2007, 211(1), 26-35.
25. Thor, A.D.; Young, R.H.; Clement, P.B. Pathology of the fallopian tube, broad ligament, peritoneum, and pelvic soft tissues. Hum. Pathol., 1991, 22(9), 856-867.
26. Du, H.; Taylor, H.S. Molecular regulation of mullerian development by Hox genes. Ann. N. Y. Acad. Sci., 2004, 1034, 152-165.
27. Cheng, W.; Liu, J.; Yoshida, H.; Rosen, D.; Naora, H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat. Med., 2005, 11(5), 531-537.
28. Naora, H. Developmental patterning in the wrong context: the paradox of epithelial ovarian cancers. Cell Cycle, 2005, 4(8), 1033-1035.
29. Hamburger, A.W.; Salmon, S.E. Primary bioassay of human tumor stem cells. Science, 1977, 197(4302), 461-463.
30. Bapat, S.A.; Mali, A.M.; Koppikar, C.B.; Kurrey, N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res., 2005, 65(8), 3025-3029.
31. Szotek, P.P.; Pieretti-Vanmarcke, R.; Masiakos, P.T.; Dinulescu, D.M.; Connolly, D.; Foster, R.; Dombkowski, D.; Preffer, F.; Maclaughlin, D.T.; Donahoe, P.K. Ovarian cancer side population defines cells with stem cell-like characteristics and Müllerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. USA, 2006, 103(30), 11154-11159.
32. Moserle, L.; Indraccolo, S.; Ghisi, M.; Frasson, C.; Fortunato, E.; Canevari, S.; Miotti, S.; Tosello, V.; Zamarchi, R.; Corradin, A.; Minuzzo, S.; Rossi, E.; Basso, G.; Amadori, A. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res., 2008, 68(14), 5658-5668.
33. Gao, Q.; Geng, L.; Kvalheim, G.; Gaudernack, G.; Suo, Z. Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct. Pathol., 2009, 33(4), 175-181.
34. Zhang, S.; Balch, C.; Chan, M.W.; Lai, H.C.; Matei, D.; Schilder, J.M.; Yan, P.S.; Huang, T.H.; Nephew, K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res., 2008, 68(11), 4311-4320.
35. Curley, M.D.; Therrien, V.A.; Cummings, C.L.; Sergent, P.A.; Koulouris, C.R.; Friel, A.M.; Roberts, D.J.; Seiden, M.V.; Scadden, D.T.; Rueda, B.R.; Foster, R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells, 2009, 8, 8.
36. Baba, T.; Convery, P.A.; Matsumura, N.; Whitaker, R.S.; Kondoh, E.; Perry, T.; Huang, Z.; Bentley, R.C.; Mori, S.; Fujii, S.; Marks, J.R.; Berchuck, A.; Murphy, S.K. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene, 2009, 28(2), 209-218.
37. Ferrandina, G.; Bonanno, G.; Pierelli, L.; Perillo, A.; Procoli, A.; Mariotti, A.; Corallo, M.; Martinelli, E.; Rutella, S.; Paglia, A.; Zannoni, G.; Mancuso, S.; Scambia, G. Expression of CD133-1 and CD133-2 in ovarian cancer. Int. J. Gynecol. Cancer, 2008, 18(3), 506-514.
38. Alvero, A.B.; Chen, R.; Fu, H.H.; Montagna, M.; Schwartz, P.E.; Rutherford, T.; Silasi, D.A.; Steffensen, K.D.; Waldstrom, M.; Visintin, I.; Mor, G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle, 2009, 8(1), 158-166.
39. Ozols, R.F. Systemic therapy for ovarian cancer: current status and new treatments. Semin. Oncol., 2006, 33(2 Suppl 6), S3-11.
40. Hedley, B.D.; Chambers, A.F. Tumor dormancy and metastasis. Adv. Cancer Res., 2009, 102, 67-101.
41. Pantel, K.; Alix-Panabieres, C.; Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol., 2009, 6(6), 339-351.
42. Winquist, R.J.; Boucher, D.M.; Wood, M.; Furey, B.F. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine. Biochem. Pharmacol., 2009, 78(4), 326-334.
43. Kwek, J.W.; Iyer, R.B. Recurrent ovarian cancer: Spectrum of imaging findings. AJR Am. J. Roentgenol., 2006, 187(1), 99-104.
44. Trumpp, A.; Wiestler, O.D. Mechanisms of disease: Cancer stem cells--targeting the evil twin. Nat. Clin. Pract. Oncol., 2008, 5(6), 337-347.
45. Levina, V.; Marrangoni, A.M.; DeMarco, R.; Gorelik, E.; Lokshin, A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE, 2008, 3(8), e3077.
46. Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 2009, 138(4), 645-659.
47. Zhou, J.; Zhang, H.; Gu, P.; Bai, J.; Margolick, J.B.; Zhang, Y. NFkappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat., 2008, 111(3), 419-427.
48. Zhou, J.; Zhang, H.; Gu, P.; Margolick, J.B.; Yin, D.; Zhang, Y. Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Res. Treat., 2009, 115(2), 269-277.
49. Beier, D.; Rohrl, S.; Pillai, D.R.; Schwarz, S.; Kunz-Schughart, L.A.; Leukel, P.; Proescholdt, M.; Brawanski, A.; Bogdahn, U.; Trampe-Kieslich, A.; Giebel, B.; Wischhusen, J.; Reifenberger, G.; Hau, P.; Beier, C.P. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res., 2008, 68(14), 5706-5715.
50. Somjen, D.; Katzburg, S.; Nevo, N.; Gayer, B.; Hodge, R.P.; Renevey, M.D.; Kalchenko, V.; Meshorer, A.; Stern, N.; Kohen, F. A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma. J. Steroid Biochem. Mol. Biol., 2008, 110(1-2), 144-149.
51. Green, J.M.; Alvero, A.B.; Kohen, F.; Mor, G. 7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: A novel compound capable of inducing cell death in epithelial ovarian cancer stem cells. Cancer Biol. Ther., 2009, 8(18), 18.
52. Jin, S.; Zhang, Q.Y.; Kang, X.M.; Wang, J.X.; Zhao, W.H. Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway. Ann. Oncol., 2010, 21(2), 263-268.
53. Doi, A.; Park, I.H.; Wen, B.; Murakami, P.; Aryee, M.J.; Irizarry, R.; Herb, B.; Ladd-Acosta, C.; Rho, J.; Loewer, S.; Miller, J.; Schlaeger, T.; Daley, G.Q.; Feinberg, A.P. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet., 2009, 41(12), 1350-1353.
54. Mathews, L.A.; Crea, F.; Farrar, W.L. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation, 2009, 78(1), 1-17.
55. Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet., 2006, 7(1), 21-33.
56. Berry, N.B.; Bapat, S.A. Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J. Ovarian Res., 2008, 1, 8.
57. Guerrero-Bosagna, C.M.; Sabat, P.; Valdovinos, F.S.; Valladares, L.E.; Clark, S.J. Epigenetic and phenotypic changes result from a continuous pre and post natal dietary exposure to phytoestrogens in an experimental population of mice. BMC Physiol., 2008, 8, 17.
58. Fang, M.Z.; Chen, D.; Sun, Y.; Jin, Z.; Christman, J.K.; Yang, C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res., 2005, 11(19 Pt 1), 7033-7041.
59. Choi, E.J.; Kim, T.; Lee, M.S. Pro-apoptotic effect and cytotoxicity of genistein and genistin in human ovarian cancer SK-OV-3 cells. Life Sci., 2007, 80(15), 1403-1408.
60. Gossner, G.; Choi, M.; Tan, L.; Fogoros, S.; Griffith, K.A.; Kuenker, M.; Liu, J.R. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol. Oncol., 2007, 105(1), 23-30. (Pubitemid 46441453)
61. Hsu, E.L.; Chen, N.; Westbrook, A.; Wang, F.; Zhang, R.; Taylor, R.T.; Hankinson, O. Modulation of CXCR4, CXCL12, and tumor cell invasion potential in vitro by phytochemicals. J. Oncol., 2009, 2009, 491985.
62. Ouyang, G.; Yao, L.; Ruan, K.; Song, G.; Mao, Y.; Bao, S. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol. Int., 2009, 33(12), 1237-1244.
63. Solomon, L.A.; Ali, S.; Banerjee, S.; Munkarah, A.R.; Morris, R.T.; Sarkar, F.H. Sensitization of ovarian cancer cells to cisplatin by genistein: The role of NF-kappaB. J. Ovarian Res., 2008, 1(1), 9.
64. Thasni, K.A.; Rojini, G.; Rakesh, S.N.; Ratheeshkumar, T.; Babu, M.S.; Srinivas, G.; Banerji, A.; Srinivas, P. Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. Eur. J. Pharmacol., 2008, 588(2-3), 158-164.
65. Dolinoy, D.C.; Huang, D.; Jirtle, R.L. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc. Natl. Acad. Sci. USA, 2007, 104(32), 13056-13061.
66. Dolinoy, D.C.; Weidman, J.R.; Waterland, R.A.; Jirtle, R.L. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environ. Health Perspect., 2006, 114(4), 567-572.
67. King-Batoon, A.; Leszczynska, J.M.; Klein, C.B. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen, 2008, 49(1), 36-45.
68. Majid, S.; Dar, A.A.; Ahmad, A.E.; Hirata, H.; Kawakami, K.; Shahryari, V.; Saini, S.; Tanaka, Y.; Dahiya, A.V.; Khatri, G.; Dahiya, R. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis, 2009, 30(4), 662-670.
69. Majid, S.; Dar, A.A.; Shahryari, V.; Hirata, H.; Ahmad, A.; Saini, S.; Tanaka, Y.; Dahiya, A.V.; Dahiya, R. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer, 2010, 116(1), 66-76.
70. Qin, W.; Zhu, W.; Shi, H.; Hewett, J.E.; Ruhlen, R.L.; MacDonald, R.S.; Rottinghaus, G.E.; Chen, Y.C.; Sauter, E.R. Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women. Nutr. Cancer, 2009, 61(2), 238-244.
71. Lou, W.; Krill, D.; Dhir, R.; Becich, M.J.; Dong, J.T.; Frierson, H.F., Jr.; Isaacs, W.B.; Isaacs, J.T.; Gao, A.C. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res., 1999, 59(10), 2329-2331.
72. Sato, S.; Yokozaki, H.; Yasui, W.; Nikai, H.; Tahara, E. Silencing of the CD44 gene by CpG methylation in a human gastric carcinoma cell line. Jpn. J. Cancer Res., 1999, 90(5), 485-489.
73. Yan, P.; Muhlethaler, A.; Bourloud, K.B.; Beck, M.N.; Gross, N. Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma. Genes Chromosomes Cancer, 2003, 36(2), 129-138.
74. Hibi, K.; Sakata, M.; Kitamura, Y.H.; Sakuraba, K.; Shirahata, A.; Goto, T.; Mizukami, H.; Saito, M.; Ishibashi, K.; Kigawa, G.; Nemoto, H.; Sanada, Y. Demethylation of the CD133 gene is frequently detected in advanced colorectal cancer. Anticancer Res., 2009, 29(6), 2235-2237.
75. Yi, J.M.; Tsai, H.C.; Glockner, S.C.; Lin, S.; Ohm, J.E.; Easwaran, H.; James, C.D.; Costello, J.F.; Riggins, G.; Eberhart, C.G.; Laterra, J.; Vescovi, A.L.; Ahuja, N.; Herman, J.G.; Schuebel, K.E.; Baylin, S.B. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res., 2008, 68(19), 8094-8103.
76. Tabu, K.; Sasai, K.; Kimura, T.; Wang, L.; Aoyanagi, E.; Kohsaka, S.; Tanino, M.; Nishihara, H.; Tanaka, S. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res., 2008, 18(10), 1037-1046.
77. Pleshkan, V.V.; Vinogradova, T.V.; Sverdlov, E.D. Methylation of the prominin 1 TATA-less main promoters and tissue specificity of their transcript content. Biochim. Biophys. Acta., 2008, 1779(10), 599-605.
78. Atkinson, S.P.; Koch, C.M.; Clelland, G.K.; Willcox, S.; Fowler, J.C.; Stewart, R.; Lako, M.; Dunham, I.; Armstrong, L. Epigenetic marking prepares the human HOXA cluster for activation during differentiation of pluripotent cells. Stem Cells, 2008, 26(5), 1174-1185.
79. Bernstein, B.E.; Mikkelsen, T.S.; Xie, X.; Kamal, M.; Huebert, D.J.; Cuff, J.; Fry, B.; Meissner, A.; Wernig, M.; Plath, K.; Jaenisch, R.; Wagschal, A.; Feil, R.; Schreiber, S.L.; Lander, E.S. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell, 2006, 125(2), 315-326.
80. Azuara, V.; Perry, P.; Sauer, S.; Spivakov, M.; Jorgensen, H.F.; John, R.M.; Gouti, M.; Casanova, M.; Warnes, G.; Merkenschlager, M.; Fisher, A.G. Chromatin signatures of pluripotent cell lines. Nat. Cell Biol., 2006, 8(5), 532-538.
81. Novak, P.; Jensen, T.; Oshiro, M.M.; Wozniak, R.J.; Nouzova, M.; Watts, G.S.; Klimecki, W.T.; Kim, C.; Futscher, B.W. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res., 2006, 66(22), 10664-10670.
82. Fiegl, H.; Windbichler, G.; Mueller-Holzner, E.; Goebel, G.; Lechner, M.; Jacobs, I.J.; Widschwendter, M. HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int. J. Cancer, 2008, 123(3), 725-729.
83. Wu, Q.; Lothe, R.A.; Ahlquist, T.; Silins, I.; Trope, C.G.; Micci, F.; Nesland, J.M.; Suo, Z.; Lind, G.E. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol. Cancer, 2007, 6, 45.
84. Widschwendter, M.; Apostolidou, S.; Jones, A.A.; Fourkala, E.O.; Arora, R.; Pearce, C.L.; Frasco, M.A.; Ayhan, A.; Zikan, M.; Cibula, D.; Iyibozkurt, C.A.; Yavuz, E.; Hauser-Kronberger, C.; Dubeau, L.; Menon, U.; Jacobs, I.J. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. Int. J. Cancer, 2009, 125(9), 2214-2218.
85. Mandell, J.G.; Barbas, C.F., 3rd, Zinc Finger Tools: custom DNAbinding domains for transcription factors and nucleases. Nucleic Acids Res., 2006, 34, W516-523.
86. Visser, A.E.; Verschure, P.J.; Gommans, W.M.; Haisma, H.J.; Rots, M.G. Step into the groove: engineered transcription factors as modulators of gene expression. Adv. Genet., 2006, 56, 131-161.
87. Segal, D.J. The use of zinc finger peptides to study the role of specific factor binding sites in the chromatin environment. Methods, 2002, 26(1), 76-83.
88. Verschure, P.J.; Visser, A.E.; Rots, M.G. Step out of the groove: epigenetic gene control systems and engineered transcription factors. Adv. Genet., 2006, 56, 163-204.
89. Snowden, A.W.; Zhang, L.; Urnov, F.; Dent, C.; Jouvenot, Y.; Zhong, X.; Rebar, E.J.; Jamieson, A.C.; Zhang, H.S.; Tan, S.; Case, C.C.; Pabo, C.O.; Wolffe, A.P.; Gregory, P.D. Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors. Cancer Res., 2003, 63(24), 8968-8976.
90. Rebar, E.J.; Huang, Y.; Hickey, R.; Nath, A.K.; Meoli, D.; Nath, S.; Chen, B.; Xu, L.; Liang, Y.; Jamieson, A.C.; Zhang, L.; Spratt, S.K.; Case, C.C.; Wolffe, A.; Giordano, F.J. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med., 2002, 8(12), 1427-1432.
91. Zhang, L.; Spratt, S.K.; Liu, Q.; Johnstone, B.; Qi, H.; Raschke, E.E.; Jamieson, A.C.; Rebar, E.J.; Wolffe, A.P.; Case, C.C. Synthetic zinc finger transcription factor action at an endogenous chromosomal site. Activation of the human erythropoietin gene. J. Biol. Chem., 2000, 275(43), 33850-33860.
92. Jouvenot, Y.; Ginjala, V.; Zhang, L.; Liu, P.Q.; Oshimura, M.; Feinberg, A.P.; Wolffe, A.P.; Ohlsson, R.; Gregory, P.D. Targeted regulation of imprinted genes by synthetic zinc-finger transcription factors. Gene Ther., 2003, 10(6), 513-522.
93. Li, C.; Feng, Y.; Coukos, G.; Zhang, L. Therapeutic microRNA strategies in human cancer. AAPS J., 2009, 11(4), 747-757.
94. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; Downing, J.R.; Jacks, T.; Horvitz, H.R.; Golub, T.R. MicroRNA expression profiles classify human cancers. Nature, 2005, 435(7043), 834-838.
95. Iorio, M.V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C.G.; Alder, H.; Calin, G.A.; Menard, S.; Croce, C.M. MicroRNA signatures in human ovarian cancer. Cancer Res., 2007, 67(18), 8699-8707.
96. Wyman, S.K.; Parkin, R.K.; Mitchell, P.S.; Fritz, B.R.; O'Briant, K.; Godwin, A.K.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Tewari, M. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS ONE, 2009, 4(4), e5311.
97. Boren, T.; Xiong, Y.; Hakam, A.; Wenham, R.; Apte, S.; Chan, G.; Kamath, S.G.; Chen, D.T.; Dressman, H.; Lancaster, J.M. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol. Oncol., 2009, 113(2), 249-255.
98. Deng, S.; Calin, G.A.; Croce, C.M.; Coukos, G.; Zhang, L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 2008, 7(17), 2643-2646.
99. Silber, J.; Lim, D.A.; Petritsch, C.; Persson, A.I.; Maunakea, A.K.; Yu, M.; Vandenberg, S.R.; Ginzinger, D.G.; James, C.D.; Costello, J.F.; Bergers, G.; Weiss, W.A.; Alvarez-Buylla, A.; Hodgson, J.G. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med., 2008, 6, 14.
100. Ji, Q.; Hao, X.; Zhang, M.; Tang, W.; Yang, M.; Li, L.; Xiang, D.; Desano, J.T.; Bommer, G.T.; Fan, D.; Fearon, E.R.; Lawrence, T.S.; Xu, L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE, 2009, 4(8), e6816.
101. Shimono, Y.; Zabala, M.; Cho, R.W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn, M.; Liu, H.; Panula, S.P.; Chiao, E.; Dirbas, F.M.; Somlo, G.; Pera, R.A.; Lao, K.; Clarke, M.F. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 2009, 138(3), 592-603.
102. Vessella, R.L.; Pantel, K.; Mohla, S. Tumor cell dormancy: an NCI workshop report. Cancer Biol. Ther., 2007, 6(9), 1496-1504.
103. Scherf, U.; Ross, D.T.; Waltham, M.; Smith, L.H.; Lee, J.K.; Tanabe, L.; Kohn, K.W.; Reinhold, W.C.; Myers, T.G.; Andrews, D.T.; Scudiero, D.A.; Eisen, M.B.; Sausville, E.A.; Pommier, Y.; Botstein, D.; Brown, P.O.; Weinstein, J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet, 2000, 24(3), 236-244. (Pubitemid 30132190)
104. Kondoh, E.; Mori, S.; Yamaguchi, K.; Baba, T.; Matsumura, N.; Barnett, J.C.; Whitaker, R.S.; Konishi, I.; Fujii, S.; Berchuck, A.; Murphy, S.K. Targeting slow-proliferating quiescent ovarian cancer cells. Int. J. Cancer, 2009, (Epub ahead of print; PMID: 19795452).